Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
A dosage of 0.75 mg of dulaglutide was highly effective in this clinical case
Phase 2 data in 2023 showed 24.2% weight loss at 48 weeks
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon (GCG) receptor This triple G mechanism targets multiple pathways for appetite control, insulin sensitivity, glucose regulation, and energy/fat metabolismpotentially offering greater effects than dual (GLP-1/GIP) or single agonists
A plateau and maintenance can look similar on the scale, but they are not the same
US$ 23.31
US$ 20.62
US$ 25.33
US$ 29.39
US$ 22.60
US$ 21.44
US$ 26.99
